About us


DeuterOncology NV was founded in September 2020 by  Dr Timothy Perera and is based in Liege in Belgium.

The company generated pre-clinical validation of DO-2, a novel, highly selective, brain penetrant deuterated MET kinase and RAS pathway inhibitor. Timothy Perera was the originator of the initial idea for the use of deuteration as a means to modulate metabolic properties of the parent drug and remains a strong champion of this exciting new molecule.

The molecule was in-licensed (worldwide rights outside of greater China) from OCTIMET Oncology NV and originally licensed from Janssen Pharmaceutica in 2017.

DeuterOncology has initiated a phase 1 clinical study to validate DO-2 as a ‘Best in Class’ MET kinase inhibitor as suggested by the strong preclinical data package. DeuterOncology works together with a broad established network of collaborators across the world to achieve its mission to bring new solutions to cancer patients.

Meet Our Founder

Timothy Perera

PhD Founder & CEO

Tim has more than 30 years global large and small Pharma experience in Target Identification, Drug Discovery and Development. Before setting up DeuterOncology, Tim was the Founder and CSO of OCTIMET oncology NV. Prior to that Tim was the Global Discovery Leader for the Lung Disease Area at J&J. Tim was recognized for the quality of the research and dedication to Janssen R&D by being made a Janssen Research Fellow in 2012. During his career at JNJ he led multiple discovery projects teams including 4 that reached the clinic. Tim was the Discovery Project Leader and Project Champion for the first globally approved FGFR kinase inhibitor Balversa (erdafitinib). Tim is a named inventor on 16 patents and coauthor on more than 40 scientific publications.

Our Team

Prof. Jaap Verweij

Chief Medical Officer

Tomas Van Dyck

Chief Financial Officer

Florence Wastelin

Director of Operations

Hilde Windels

Business Development

Desiree Kanters

Clinical Operations

Our Board

Staf van Reet

Independent Chairperson

Els Hubloux

Investor Director

Serge Sagodira

Investor Director

Hélène Sabatel

Investor Director

Timothy Perera


Guy Heynen

Board Observer

Tomoko Asaoka

Board Observer

Pierre Detrixhe

Board Observer

Our Investors

Newton Biocapital

Newton Biocapital (NBC) is a VC
firm focused on early-stage life sciences companies targeting chronic health
conditions. NBC is among the eight VC firms certified by AMED in Japan to boost
the pharma ecosystem and the only one with offices in Japan /Europe. NBC’s
diversified team of experts and its presence in Japan/Europe enable NBC to
identify and select the most promising companies based on the outstanding
research ecosystem in these two regions. NBC provides investment opportunities
that can help patients and society, as well as foster growth of the
Japanese/European biotech ecosystems.

NBC is a hands-on investor and
leverages its expertise to help its portfolio companies focus on the right
indication and clinical trial design, thereby helping them progress
successfully through the challenging early drug development phases up to the
proof of concept in patients. NBC enables time- and cost-effective translation
from science to proof of concept in patients that attracts potential acquirers
and unlocks value – for patients, companies and investors.

InvestSud Tech

Investsud Tech is a specialized VC fund investing in seed and early-stage startups. Its portfolio of companies features some of the leading young technological companies in Wallonia. The fund belongs to the INVESTSUD Group, which is a private equity firm located in Wallonia, Belgium, and dedicated to accompanying small and medium-sized family companies, with equity or quasi-equity funds.


Noshaq is an investment fund and project developer with a portfolio of more than 450 companies. Noshaq is the reference financial partner for the creation and development of SMEs in the Liege region (Belgium). Over the years, Noshaq has developed a variety of financing vehicles, which are fully in line with market needs and trends, as well as its strategy. All services offered by Noshaq are always designed according to the needs and requirements of the client investor. The goal is to ensure a leverage effect on the development of the companies in our portfolio.